Page 1067 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

14 References

402. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology trial comparing a high-loading dose regimen with standard dos-
and outcome of mould infections in hematopoietic stem cell ing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297.
transplant recipients. Clin Infect Dis. 2002;34(7):909-917. 419. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La
403. Denning DW. Invasive aspergillosis. Clin Infect Dis. Camara R. Clinical applicability of the new EORTC/MSG clas-
1998;26(4):781-803. sification for invasive pulmonary aspergillosis in patients with
404. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, hematological malignancies and autopsy-confirmed invasive
clinical manifestations, and therapy. Infect Dis Clin North Am. aspergillosis. Ann Hematol. February 2003;82(2):80-82.
2002;16(4):875-894, vi. 420. Cornely OA. Aspergillus to Zygomycetes: causes, risk fac-
405. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic tors, prevention, and treatment of invasive fungal infections.
invasive fungal infections in immunocompromised patients Infection. 2008;36(4):296-313.
with cancer and hematopoietic stem cell transplants: an inter- 421. Aisner J, Schimpff SC, Bennett JE, Young VM, Wiernik PH.
national consensus. Clin Infect Dis. 2002;34(1):7-14. Aspergillus infections in cancer patients. Association with fire-
406. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions proofing materials in a new hospital. JAMA. 1976;235(4):411-412.
of invasive fungal disease from the European Organization 422. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds
for Research and Treatment of Cancer/Invasive Fungal (including Aspergillus species) in hospital water distribu-
Infections Cooperative Group and the National Institute tion systems: a 3-year prospective study and clinical impli-
of Allergy and Infectious Diseases Mycoses Study Group cations for patients with hematologic malignancies. Blood.
(EORTC/MSG) Consensus Group. Clin Infect Dis. June 15 2003;101(7):2542-2546.
2008;46(12):1813-1821. 423. Hay RJ, Clayton YM, Goodley JM. Fungal aerobiology: how,
407. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. when and where? J Hosp Infect. 1995;30(suppl):352-357.
Epidemiology of invasive aspergillosis in France: a six-year 424. Arnow PM, Andersen RL, Mainous PD, Smith EJ. Pumonary
multicentric survey in the Greater Paris area. J Hosp Infect. aspergillosis during hospital renovation. Am Rev Respir Dis.
2002;51(4):288-296. 1978;118(1):49-53.
408. Martino R, Subira M, Rovira M, et al. Invasive fungal infec- 425. Cooper EE, O’Reilly MA, Guest DI, Dharmage SC. Influence
tions after allogeneic peripheral blood stem cell transplanta- of building construction work on Aspergillus infection in a
tion: incidence and risk factors in 395 patients. Br J Haematol. hospital setting. Infect Control Hosp Epidemiol. 2003;24(7):
2002;116(2):475-482. 472-476.
409. Greene R. The radiological spectrum of pulmonary aspergil- 426. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration
losis. Med Mycol. 2005;43(suppl 1):S147-S154. on nosocomial Aspergillus infections. Unique risk of bone mar-
410. Primack SL, Hartman TE, Lee KS, Muller NL. Pulmonary row transplant recipients. Am J Med. 1987;83(4):709-718.
nodules and the CT halo sign. Radiology. 1994;190(2):513-515. 427. Passweg JR, Rowlings PA, Atkinson KA, et al. Influence
411. Lee YR, Choi YW, Lee KJ, Jeon SC, Park CK, Heo JN. CT of protective isolation on outcome of allogeneic bone mar-
halo sign: the spectrum of pulmonary diseases. Br J Radiol. row transplantation for leukemia. Bone Marrow Transplant.
September 2005;78(933):862-865. 1998;21(12):1231-1238.
412. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis 428. Construction-related nosocomial infections in patients in health
DP. Predictors of pulmonary zygomycosis versus invasive pul- care facilities. Decreasing the risk of Aspergillus, Legionella and
monary aspergillosis in patients with cancer. Clin Infect Dis. other infections. Can Commun Dis Rep. 2001;27(suppl 2):i-42.
2005;41(1):60-66. 429. Streifel AJ, Mayhall CG. Design and maintenance of hospital
413. Weisser M, Rausch C, Droll A, et al. Galactomannan does not ventilation systems and prevention of airborne nosocomial
precede major signs on a pulmonary computerized tomographic infections. Hospital Epidemiology and Infection Control.
scan suggestive of invasive aspergillosis in patients with hema- Vol 2. Philadelphia, PA: Lippincott, Williams & Wilkins;
tological malignancies. Clin Infect Dis. 2005;41(8):1143-1149. 1999:1211-1221.
414. Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection 430. Centers for Disease Control. Isolation techniques for use in hos-
of Aspergillus galactomannan by enzyme immunoabsorbent pitals. US Government Printing Office; 1976.
assay in recipients of allogeneic hematopoietic stem cell trans- 431. Cornet M, Levy V, Fleury L, et al. Efficacy of prevention
plantation: a prospective study. Transplantation. April 27, by high-efficiency particulate air filtration or laminar air-
2004;77(8):1260-1264. flow against Aspergillus airborne contamination during hos-
415. Williamson EC, Oliver DA, Johnson EM, Foot AB, Marks DI, pital renovation. Infect Control Hosp Epidemiol. 1999;20(7):
Warnock DW. Aspergillus antigen testing in bone marrow 508-513.
transplant recipients. J Clin Pathol. May 2000;53(5):362-366. 432. Eckmanns T, Ruden H, Gastmeier P. The influence of high-
416. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings efficiency particulate air filtration on mortality and fungal
in acute invasive pulmonary aspergillosis: clinical significance infection among highly immunosuppressed patients: a system-
of the halo sign. Clin Infect Dis. 2007;44(3):373-379. atic review. J Infect Dis. 2006;193(10):1408-1418.
417. Cornely OA, Maertens J, Bresnik M, et al. Efficacy outcomes 433. Bow EJ. Prophylaxis. In: Kleinberg M, ed. Managing Infections in
in a randomised trial of liposomal amphotericin B based on Patients with Hematological Malignancies. New York: Humana
revised EORTC/MSG 2008 definitions of invasive mould dis- Press; 2009:259-308.
ease. Mycoses. October 11, 2011;54(5):e449-e455. 434. Denning DW, Stevens DA. Antifungal and surgical treatment of
418. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphoteri- invasive aspergillosis: review of 2,121 published cases. Rev Infect
cin B as initial therapy for invasive mold infection: a randomized Dis. 1990;12(6):1147-1201.

Section05-O-ref.indd 14 1/20/2015 4:51:20 PM